Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 30, 2007

Oncolytics Biotech Completes Initial Scale-Up of Manufacturing Process for Reolysin

  • Oncolytics Biotech reports the successful initial scale-up of the manufacturing process for its anticancer candidate. Reolysin is a formulation of the human reovirus and is in clinical trials for treating Ras-activated tumor cells and some cellular proliferative disorders.

    The process improvements and scale up to a 40-L batch size resulted in increased total yields of at least 20,000 doses at the maximum clinical dose for intravenous use or 60,000 doses for local use, notes Matt Coffey, Ph.D., CSO of Oncolytics.

    This was achieved through advancements in the media formulation used in the primary production of Reolysin developed by SAFC Biosciences. Additionally, downstream processing steps required to generate finished product were also improved. The scale-up of primary production and downstream processing development was undertaken by the National Research Council Biotechnology Research Institute (NRC-BRI).



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »